Halavaara, Mika
Martelius, Timi
Järvinen, Asko
Antikainen, Jenni
Kuusela, Pentti
Salminen, Ulla-Stina
Anttila, Veli-Jukka
Funding for this research was provided by:
Helsingin ja Uudenmaan Sairaanhoitopiiri (No number)
Article History
Received: 18 September 2018
Accepted: 5 December 2018
First Online: 24 January 2019
Compliance with ethical standards
:
: Authors report no conflict of interest related to the study. MH has received congress invitation from Gilead; lecture fees from MSD, Ratiopharm and Orion Pharma and has recent consultancies with Pfizer. TM has received congress invitation from Pfizer, CSL Behring and Gilead; lecture fees from CSL Behring and Octapharma and a grant from Sanguin. AJ has received conference invitation from MSD; lecture fees from Astellas, Unimedic, Cardiome, Pfizer, MSD, Ratiopharm, and Orion Pharma and has recent consultancies with Unimedic. JA has no conflict of interest. PK has no conflict of interest. USS has no conflict of interest. VJA has received lecture fees from Astellas, Roche, MSD, and Pfizer and has recent consultancies with MSD and Pfizer and study participation with Astellas and MSD.
: The research board of the Inflammation Center at the Helsinki University Hospital approved the study protocol. Approval of Research Ethics Committee was not needed for this study.
: Not needed given the nature of this retrospective observational study.